Pole Hospitalier Jolimont

Research site

Belgium Rue Ferrer 159, 7100 La Louviere, Belgium

4 trials recruiting
Acute myeloid leukaemia · Hormone receptor positive HER2 negative breast cancer · Non-small cell lung cancer
Adults and children

About Specializations

Pole Hospitalier Jolimont in La Louviere, Belgium specialises in clinical trials of conditions such as Acute myeloid leukaemia, Hormone receptor positive HER2 negative breast cancer, Non-small cell lung cancer, Adenocarcinoma pancreas, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Rue Ferrer 1597100 La LouviereBelgium

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 13

More sites in La Louviere Belgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

14 clinical trials

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

Study on Preoperative Treatment with mFOLFIRINOX or Gemcitabine-Paclitaxel for Patients with Borderline Resectable Pancreatic Cancer

Registered drugNo placebo

Study on Preoperative Treatment with mFOLFIRINOX or Gemcitabine-Paclitaxel for Patients with Borderline Resectable Pancreatic Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Hopital Erasme

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Unicancer

Contact Research Centre

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Eli Lilly & Co.

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Servier Affaires Medicales

Contact Research Centre

Pneumonia

Not yet recruiting

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drugNo placebo

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Baricitinib
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Gilteritinib
Sponsor:Haemato Oncology Foundation For Adults Netherlands

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Enasidenib Mesilate
Sponsor:Haemato Oncology Foundation For Adults Netherlands

Contact Research Centre

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Apalutamide
Sponsor:Janssen Cilag International

Contact Research Centre

Monkeypox

Not recruiting

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Registered drugNo placebo

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Registered drugNo placebo

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tecovirimat
Sponsor:University Of Oxford

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites